Cara Therapeutics Inc (NASDAQ:CARA) gapped down prior to trading on Wednesday . The stock had previously closed at $13.17, but opened at $16.93. Cara Therapeutics shares last traded at $17.13, with a volume of 97,286 shares.

A number of research analysts recently issued reports on the company. ValuEngine upgraded Cara Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Cara Therapeutics in a research note on Tuesday. Zacks Investment Research downgraded shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, October 8th. Needham & Company LLC restated a “buy” rating and set a $35.00 price target on shares of Cara Therapeutics in a research report on Tuesday. Finally, BidaskClub raised shares of Cara Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $26.93.

The firm has a 50-day moving average of $21.49 and a 200 day moving average of $21.62. The company has a current ratio of 4.21, a quick ratio of 4.21 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $1.04 billion, a price-to-earnings ratio of -8.33 and a beta of 2.30.

Cara Therapeutics (NASDAQ:CARA) last announced its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.59) by ($0.15). Cara Therapeutics had a negative return on equity of 70.35% and a negative net margin of 470.70%. The business had revenue of $5.79 million for the quarter, compared to analyst estimates of $5.56 million. Equities research analysts predict that Cara Therapeutics Inc will post -2.55 EPS for the current fiscal year.

In related news, SVP Frederique Ph.D. Menzaghi sold 4,000 shares of Cara Therapeutics stock in a transaction on Friday, October 4th. The stock was sold at an average price of $19.19, for a total value of $76,760.00. Following the transaction, the senior vice president now directly owns 75,886 shares in the company, valued at approximately $1,456,252.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Derek T. Chalmers sold 10,000 shares of the stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $18.28, for a total value of $182,800.00. Following the completion of the transaction, the chief executive officer now owns 933,468 shares of the company’s stock, valued at approximately $17,063,795.04. The disclosure for this sale can be found here. Insiders sold a total of 36,000 shares of company stock valued at $692,495 over the last three months. 5.80% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the company. Aperio Group LLC acquired a new stake in Cara Therapeutics during the 2nd quarter worth about $88,000. Russell Investments Group Ltd. acquired a new stake in shares of Cara Therapeutics during the third quarter worth approximately $110,000. Penserra Capital Management LLC purchased a new position in Cara Therapeutics during the third quarter valued at approximately $180,000. Squarepoint Ops LLC purchased a new position in Cara Therapeutics during the third quarter valued at approximately $190,000. Finally, Sfmg LLC acquired a new position in Cara Therapeutics in the 2nd quarter valued at approximately $200,000. Institutional investors and hedge funds own 76.08% of the company’s stock.

Cara Therapeutics Company Profile (NASDAQ:CARA)

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

Recommended Story: Why Invest in Dividend Achievers?

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.